1: Basic Research and Clinical Implications in IBD.- Section I: Predisposing Factors in the Etiology of IBD: What We Can Learn from Animal Models.- 1 Subclinical markers of human IBD.- 2 Genetic factors in animal models of intestinal inflammation.- 3 Multifactorial control of autoimmune insulin-dependent diabetes in NOD mice: lessons for inflammatory bowel disease.- 4 Genetics of complex diseases: from mouse to man and back.- Section II: Predisposing Factors in the Etiology of IBD: Bugs, Drugs and Leaks.- 5 Crohn’s disease: the pathogenesis of a granulomatous vasculitis: a hypothesis.- 6 Intestinal permeability: the basics.- Section III: Predisposing Factors in the Etiology of IBD: Is There a Primary Immune Defect?.- 7 Etiology of organ-specific autoimmunity.- 8 Regulation of mucosal immune responses — the missing link in IBD?.- 9 T cell repertoire and IBD.- 10 On the pathogenesis trail: what marker B cell clones tell us about IBD.- Section IV: Pathophysiology of Intestinal Inflammation: Intracellular and Intercellular Signalling.- 11 Growth factors in IBD.- 12 Nitric oxide and chronic colitis.- Section V: Pathophysiology of Intestinal Inflammation: Symptom Generation In IBD.- 13 Cytokine interactions with epithelium.- 14 Immunomodulation of epithelium.- 15 The enteric nervous system in intestinal inflammation.- 16 The role of smooth muscle in intestinal inflammation.- 17 Brain—gut interactions in IBD: mechanisms of anorexia in animal models of experimental colitis.- 2: Trends in IBD Therapy 1994.- Section VI: Critical Appraisal of Clinical Trials.- 18 How to critically appraise a clinical trial.- 19 Finding the right index for IBD.- 20 Special problems associated with surgical trials in IBD.- 21 Trends in IBD therapy: a meta-analytic approach.- Section VII: BasicScience: Genetics, Markers and Models.- 22 New IBD markers: definition of disease heterogeneity.- 23 Lessons in IBD pathogenesis from new animal models of spontaneous colitis.- 24 Potential human models of IBD.- Section VIII: Basic Science: Pathogenesis.- 25 New concepts of pathogenesis in IBD.- 26 The gut—brain axis in IBD: an investigator’s perspective.- 27 Gut—brain interactions in IBD: a clinician’s perspective.- Section IX: Surgical Issues in IBD.- 28 Cancer risk in IBD.- 29 Management of stomal complications.- 30 Indications and contraindications to reconstructive surgery in ulcerative colitis.- 31 Pouchitis — what’s new in etiology and management?.- 32 Laparoscopic techniques: what is the role in IBD?.- Section X: Lifestyle in IBD.- 33 Smoking.- 34 Nutritional advice.- 35 IBD, the oral contraceptive pill and pregnancy.- 36 The social toll of IBD.- 37 Insurance rating of patients with IBD: a report of a conference on morbidity and mortality.- Section XI: Therapeutics.- 38 Overview of 5-ASA in the therapy of IBD.- 39 Immunosuppressive agents in IBD: current status and future prospects.- 40 Novel targets for anti-inflammatory therapy in IBD.- Section XII: Therapy in IBD in 1994.- 41 A gastroenterologist’s perspective of the medical management of patients with Crohn’s disease and ulcerative colitis.- 42 Therapy of IBD in 1994: a surgeon’s perspective.